Who Is Buying Intuitive Surgical? Hedge Fund Activity in 2026
See which hedge funds are buying, selling, or holding Intuitive Surgical (ISRG) based on latest 13F filings. 8 funds buying, institutional value $27.5B.
8 min czytaniaFact-checked against primary sources on · figures re-verified on regulator, issuer or SEC filings — not copied from other sites
Who Is Buying Intuitive Surgical? Hedge Fund Activity in 2026
Intuitive Surgical (ISRG) is the undisputed leader in robotic-assisted surgery, and its da Vinci surgical systems have become a fixture in operating rooms worldwide. With the stock trading around $452 per share, the question on every investor's mind is: are the biggest hedge funds buying or selling ISRG?
We analyzed the latest SEC 13F filings from 35 major hedge funds and institutional investors to answer that exact question. The verdict? Institutional sentiment for Intuitive Surgical is decisively bullish — with nearly half of all tracked funds increasing their positions.
Quick Answer
Across the funds we read directly from SEC filings, the largest Intuitive Surgical position in the Q2 2026 13Fs (period ending 30 June 2026) is Renaissance Technologies at $201M (504,430 shares). Measured against the size of each filer's book rather than in dollars, the most concentrated holder is Renaissance Technologies, where Intuitive Surgical is 0.3% of everything they report. Every figure here is aggregated by CUSIP from the filer's own information table with put/call rows excluded — a 13F lists options beside shares, and adding them together is what produces the inflated stakes quoted elsewhere. Filings lag roughly 45 days: this is positioning as of 30 June 2026, not today, and not investment advice.
ISRG Key Stats at a Glance
| Metric | Value |
|---|---|
| Ticker | ISRG |
| Price | ~$452.19 |
| Active Funds Tracked | 17 |
| Funds Buying | 8 |
| Funds Selling | 4 |
| Funds Holding | 5 |
| Sentiment | Bullish |
Out of 17 actively tracked funds holding ISRG, 8 are buying, 4 are selling, and 5 are holding steady. That's a 2:1 buy-to-sell ratio — a strong institutional endorsement for a stock at all-time highs.
Who holds Intuitive Surgical, and how much it matters to them
Read from each filer's Q2 2026 information table (period ending 30 June 2026).
| Fund | Position | Shares | Share of the fund's 13F book |
|---|---|---|---|
| Renaissance Technologies | $201M | 504,430 | 0.3% of $72.62B |
| Citadel Advisors | $187M | 470,076 | 0.1% of $171.84B |
| Millennium Management | $164M | 413,337 | 0.1% of $142.92B |
| Bridgewater Associates | $7.7M | 19,324 | 0.0% of $24.38B |
The last column is the one worth reading. A multi-strategy fund reporting a $100B+ book can hold a large dollar amount of Intuitive Surgical that means almost nothing to it, while a concentrated fund holding less in dollars may have several percent of its entire book in the name. Rankings by dollar value hide exactly that difference.
Who added and who cut
Comparing each filer's Q1 2026 table with its Q2 2026 one, by share count — the change is what shows conviction, not the size of the position.
| Fund | Q1 2026 shares | Q2 2026 shares | Change |
|---|---|---|---|
| Renaissance Technologies | 139,402 | 504,430 | +262% |
| Citadel Advisors | 1,356,011 | 470,076 | -65% |
| Millennium Management | 910,292 | 413,337 | -55% |
| Bridgewater Associates | 17,294 | 19,324 | +12% |
A fund absent from this table reported no Intuitive Surgical position in either quarter.
Savings in one bank, investments in another? See it all in one place — and how many months it could carry you.
See your Freedom Runway — freeWhat This Signals for ISRG Investors
The institutional picture for Intuitive Surgical is clearly bullish. Here's what the data tells us:
The bull case is strong. An 8-to-4 buy-sell ratio with major funds like Millennium ($672M) and Citadel ($470M) increasing is a robust signal. These funds have armies of analysts, proprietary data, and sophisticated models — and they're all saying "buy more."
Sellers are profit-taking, not fleeing. The selling funds are quant-oriented shops that regularly rotate positions. D.E. Shaw still holds nearly $600M — that's not bearish behavior. It's systematic rebalancing.
Healthcare specialists are bullish. Baker Bros, which focuses exclusively on healthcare and biotech, increasing their position adds sector-specific validation to the thesis.
Valuation isn't deterring smart money. At $452 per share, ISRG isn't cheap by any traditional metric. Yet institutional buyers are adding aggressively, suggesting they see the robotic surgery market as still early in its adoption curve.
The da Vinci platform's installed base continues to grow, procedure volumes are climbing, and the razor-and-blade business model (systems + instruments + services) generates recurring revenue that institutional investors love. Each system placed generates years of high-margin instrument and service revenue — a business model that funds like Millennium and Citadel find particularly attractive because of its predictability.
With competitors still years behind, ISRG's moat appears wide enough to justify premium pricing. The recent launch of the da Vinci 5 system adds another growth vector, with early adoption metrics reportedly exceeding internal expectations. This next-generation platform could accelerate the replacement cycle and expand into new surgical specialties.
The convergence of robotic surgery with AI-powered surgical assistance also positions Intuitive Surgical at the intersection of two major investment themes — healthcare innovation and artificial intelligence. This dual narrative likely explains why both healthcare-focused funds (Baker Bros) and tech-oriented managers (Coatue) are increasing simultaneously.
For individual investors, the message from Wall Street's biggest players is clear: Intuitive Surgical remains a core holding in institutional portfolios, and the smart money is still accumulating.
Track ISRG Institutional Activity in Real Time
Want to know the moment a major fund changes its ISRG position? Track ISRG institutional moves in real-time with Freenance Smart Money — we track 35 funds with $21.4T total AUM across 77,111 positions.
👉 app.freenance.io/smart-money/ticker/ISRG
Don't wait for the next 13F filing deadline to find out what hedge funds are doing. Freenance Smart Money gives you institutional-grade insights the moment they become available — so you can make informed decisions about your portfolio, not guesses.
Related Articles
- Who Is Buying NVIDIA? Hedge Fund Activity in 2026
- Who Is Buying Apple? Hedge Fund Activity in 2026
- Who Is Buying Tesla? Hedge Fund Activity in 2026
FAQ
Why are hedge funds buying Intuitive Surgical (ISRG)?
Index managers such as Vanguard, BlackRock and State Street hold the largest raw positions in almost every large-cap name, because they track the index rather than pick the stock. Among the active filers we read directly from EDGAR, the largest position in the Q2 2026 filings is Renaissance Technologies at $201M (504,430 shares).
What role does da Vinci 5 play in the institutional thesis?
The next-generation da Vinci 5 platform expands surgical capability and is expected to accelerate the replacement cycle within Intuitive's installed base. For institutions, this adds a fresh growth vector on top of procedure volume expansion. Early adoption metrics have reportedly tracked above internal targets.
Are the funds selling ISRG bearish on the company?
Most sellers — D.E. Shaw, Two Sigma, Renaissance — are quantitative shops trimming systematically rather than abandoning the thesis. D.E. Shaw still holds nearly $600M after trimming, which suggests profit-taking and rebalancing, not a change in fundamental view. No tracked fund has exited entirely.
Why does ISRG's high valuation not deter institutional buyers?
Despite a premium multiple, funds are adding because they view robotic surgery as early in its adoption curve, with a wide moat protected by surgeon training, instrument lock-in, and regulatory hurdles. The recurring revenue base also commands a higher multiple than typical hardware businesses. Whether the valuation is justified remains an open question for any individual investor.
What does Coatue and Baker Bros buying together indicate?
Coatue is technology-focused while Baker Bros is healthcare-focused, so simultaneous accumulation means two different investment lenses see Intuitive Surgical as attractive. Robotic surgery sits at the intersection of healthcare innovation and AI-driven automation, which appeals to both mandates. This page is informational only and not investment advice.